Cargando…
Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645560/ http://dx.doi.org/10.1186/2051-1426-3-S2-P153 |
| _version_ | 1782400840280047616 |
|---|---|
| author | Haas, Naomi B Stein, Mark N Tutrone, Ronald Perini, Rodolfo Denker, Andrew Mauro, David Fong, Lawrence |
| author_facet | Haas, Naomi B Stein, Mark N Tutrone, Ronald Perini, Rodolfo Denker, Andrew Mauro, David Fong, Lawrence |
| author_sort | Haas, Naomi B |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645560 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46455602015-11-20 Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial Haas, Naomi B Stein, Mark N Tutrone, Ronald Perini, Rodolfo Denker, Andrew Mauro, David Fong, Lawrence J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645560/ http://dx.doi.org/10.1186/2051-1426-3-S2-P153 Text en Copyright © 2015 Haas et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Haas, Naomi B Stein, Mark N Tutrone, Ronald Perini, Rodolfo Denker, Andrew Mauro, David Fong, Lawrence Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title | Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title_full | Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title_fullStr | Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title_full_unstemmed | Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title_short | Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial |
| title_sort | phase i-ii study of adxs31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mcrpc): the keynote-046 trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645560/ http://dx.doi.org/10.1186/2051-1426-3-S2-P153 |
| work_keys_str_mv | AT haasnaomib phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT steinmarkn phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT tutroneronald phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT perinirodolfo phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT denkerandrew phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT maurodavid phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial AT fonglawrence phaseiiistudyofadxs31142aloneandincombinationwithpembrolizumabinpatientswithpreviouslytreatedmetastaticcastrationresistantprostatecancermcrpcthekeynote046trial |